72.11.Z - Scientific research and development activities
21.20.Z - Manufacture of pharmaceutical preparations and other pharmaceutical products
70.22.Z - Head office activities and management consultancy
71.12.Z - Engineering activities and related technical consultancy
71.20 - Technical testing and analysis
71.20.B - Inspection and issuing opinions on the technical condition of chimneys and ventilation ducts
72.19.Z - Scientific research and development activities
74.90.Z - Other professional, scientific and technical activities, not elsewhere classified
2020 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | -0,8 | -0,7 | -3,8 | -447,2 |
EBITDA | -0,6 | -0,5 | -3,6 | -680,4 |
Short time liabilities | 0,3 | 0 | 0,1 | 141,2 |
Equity capital | 0,3 | 0,5 | -2,5 | -565,4 |
Operating profit (EBIT) | -0,6 | -0,5 | -3,6 | -640,1 |
Assets | 8,2 | 8,8 | 0,2 | -97,5 |
Net profit (loss) | -0,8 | -0,7 | -3,8 | -456,8 |
Cash | 0,5 | 0,2 | 0 | -84,2 |
Net income from sale | 0,1 | 0,1 | 0,1 | 44,9 |
Liabilities and provisions for liabilities | 8 | 8,2 | 2,7 | -67,4 |
Working assets | 0,5 | 0,3 | 0,2 | -49,6 |
Depreciation | 0 | 0 | 0 | -24,1 |
% | % | % | p.p. | |
Profitability of capital | -290,2 | -128,7 | 154 | 282,7 |
Equity capital to total assets | 3,4 | 6 | -1115 | -1121 |
Gross profit margin | -771,3 | -780,1 | -2945,4 | -2165,3 |
EBITDA Margin | -586,6 | -522,5 | -2814,1 | -2291,6 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 1042 | 167 | 278 | 111 |
Current financial liquidity indicator | 0.09421325474977493 | 0.054153505712747574 | 1.6131489276885986 | 1,5 |
Net dept to EBITDA | -3.0958259105682373 | -4.749069690704346 | -0.6984701156616211 | 4 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane